Gyre TherapeuticsGYRE +1.29%39 Altman Z-Score is 17.43 as of Jun. 27, 2026, which is 7% below its 10-year median of 18.83. GuruFocus rates GYRE with a GF Score™ of 39/100 and a GF Value™ of $9.82 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 934 Biotechnology companies, Gyre Therapeutics ranks better than 86.72% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 17.43 is strong.
Gyre Therapeutics has a Altman Z-Score of 17.43, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Gyre Therapeutics's Altman Z-Score or its related term are showing as below:
GYRE'
s Altman Z-Score Range Over the Past 10 Years
Min: 9.66 Med: 18.83 Max: 25.52
Current: 17.43
During the past 5 years, Gyre Therapeutics's highest Altman Z-Score was 25.52. The lowest was 9.66. And the median was 18.83.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Gyre Therapeutics Altman Z-Score Related Terms
Gyre Therapeutics Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Gyre Therapeutics's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GYRE vs CBIO, RIGL, ARVN: Altman Z-Score Comparison
For the Biotechnology subindustry, Gyre Therapeutics's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gyre Therapeutics Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Gyre Therapeutics's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Gyre Therapeutics's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.4441
+
1.4
*
-0.4794
+
3.3
*
0.0035
+
0.6
*
28.0615
+
1.0
*
0.7225
=
17.43
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Gyre Therapeutics (GYRE) has a Altman Z-Score of 17.43 as of Jun. 27, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Gyre Therapeutics and its competitors. This is near median its historical median of 18.83. Over the past decade, Gyre Therapeutics' Altman Z-Score has ranged from 9.66 to 25.52. According to the industry distribution chart, Gyre Therapeutics ranks #124 out of 934 companies in the Biotechnology industry, placing it in the top 13.3%.
Is Gyre Therapeutics' Altman Z-Score too high?
Gyre Therapeutics' current Altman Z-Score of 17.43 is near median its 10-year median of 18.83. Over the past 10 years, this metric has ranged from a low of 9.66 to a high of 25.52. The Biotechnology industry median Altman Z-Score is 2.63. Gyre Therapeutics' value of 17.43 is 564% above this industry median. Based on the distribution chart, Gyre Therapeutics ranks #124 out of 934 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Gyre Therapeutics has a GF Score™ of 39/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gyre Therapeutics' Altman Z-Score compare to CBIO and RIGL?
According to the Biotechnology industry distribution chart, Gyre Therapeutics ranks #124 out of 934 companies for Altman Z-Score. This places Gyre Therapeutics in the top 13% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.63. Gyre Therapeutics' value of 17.43 is 564% above this benchmark. Historically, Gyre Therapeutics' own Altman Z-Score has ranged from 9.66 to 25.52 over the past decade. While the company's 10-year median is 18.83 vs. the industry median of 2.63, Gyre Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.63, based on 934 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gyre Therapeutics's current Altman Z-Score of 17.43 is 564% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Gyre Therapeutics and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gyre Therapeutics's current Altman Z-Score is 17.43, which is near median its own 10-year median of 18.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gyre Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Gyre Therapeutics (GYRE) is currently considered Significantly Undervalued. The stock's GF Value™ is $9.82, compared to a current price of $6.30 — trading 35.8% below its estimated fair value. The current Altman Z-Score is 17.43, which is near median its 10-year median of 18.83 and 564% above the Biotechnology industry median of 2.63. Gyre Therapeutics' overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Gyre Therapeutics (GYRE), the current Altman Z-Score is 17.43 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gyre Therapeutics (GYRE) Overvalued in 2026?
Based on GuruFocus' analysis, Gyre Therapeutics stock appears to be undervalued.
The current stock price of $6.30 is trading 35.8% below its estimated GF Value™ of $9.82.
GuruFocus considers Gyre Therapeutics to be Significantly Undervalued.
Key valuation signals for GYRE:
Altman Z-Score: 17.43 (near median its 10-year median of 18.83)
GF Value™: $9.82 vs. price of $6.30 (35.8% below fair value)
Industry Position: 564% above the Biotechnology median (#124 of 934)
No single metric tells the full story. See the GYRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
39GF Score
Get the complete analysis for GYRE
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GYRE has been successfully added to your 
